- 2 updates
The body that recommends what drugs can and cannot be paid for now says a drug once hailed as a breakthrough is not "cost effective".
A man from Lincolnshire who won his fight against prostate cancer has joined the ranks of those calling for Arbiraterone to remain available:
Six years ago Abiraterone was hailed as a medical breakthrough that could offer men extra time with loved ones and a chance to delay chemotherapy and its debilitating side effects.
Today the body that recommends what can and cannot be paid for said it 'wasn't cost effective'.
Prostate cancer patients have now been told that the life-extending drug will not be routinely prescribed unless they have chemotherapy.
One man from North Yorkshire who is fighting prostate cancer is calling for a rethink: